Quelicin

Quick links to important sections

Quelicin

Selected form

Method of action: Muscle Relaxant

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quelicin

Property Description
Active ingredient Suxamethonium Chloride (Succinylcholine Chloride)
Form Sterile solution for injection
Pharmacological class Depolarizing Neuromuscular Blocking Agent
General purpose Facilitates critical procedures requiring temporary muscle paralysis
Origin Synthetic, quaternary ammonium compound

Quelicin is a specialized, prescription-only medication whose use is strictly confined to controlled clinical environments like operating rooms. Its active substance, Suxamethonium Chloride, is a synthetic chemical entity classified as a neuromuscular blocking agent and a specialized skeletal muscle relaxant. It has a rapid and predictable onset of action.


Quelicin: Definition and Pharmacological Classification

Quelicin belongs to the class of depolarizing neuromuscular blocking agents. This classification indicates that the drug achieves muscle relaxation by persistently activating the muscle receptors, leading to temporary unresponsiveness or paralysis. This unique action makes the drug suitable for critical interventions.


What is the Form and General Purpose of Quelicin?

Quelicin is administered as a clear, sterile solution exclusively via injection, primarily through the intravenous route. The preparation is an aqueous solution, meaning the active substance is dissolved in sterile water. The general purpose of Quelicin is to rapidly and reliably achieve complete, temporary muscle stillness, which is essential to safely secure a patient's airway via tracheal intubation during the induction of general anesthesia. This highly specialized function allows for the performance of critical, time-sensitive interventions.


How Does Quelicin Differ from Other Muscle Relaxants?

Quelicin is pharmacologically distinct from other, more common nondepolarizing muscle relaxants primarily due to its ultra-short duration of action and unique breakdown pathway. The effects of the medication wear off quickly because it is rapidly metabolized in the plasma by the enzyme pseudocholinesterase. This characteristic rapid onset and swift recovery makes the drug suitable for emergency procedures that necessitate immediate paralysis and subsequent rapid return of muscle function.

Regulatory References

  1. WHO Essential Medicines List (EML) for Suxamethonium
  2. NIH DailyMed for Succinylcholine Chloride

What side effects are possible with Quelicin?

Possible Side Effects and Safety Information

The safety profile of Quelicin (Suxamethonium Chloride) is strictly defined by regulatory documents, emphasizing the potential for immediate and profound systemic effects inherent to its use as a neuromuscular blocking agent. Adverse reactions are officially classified, with a focus on serious outcomes affecting the cardiovascular and musculoskeletal systems.

Officially Documented Adverse Reactions

Adverse effects are grouped by the affected System-Organ Class (SOC) in official labeling:

  • Cardiac Disorders: Include severe events such as cardiac arrest, bradycardia (slowed heart rate), and various arrhythmias.
  • Musculoskeletal Disorders: Key concerns are Malignant Hyperthermia (a potentially fatal hypermetabolic state), rhabdomyolysis, muscle fasciculations (twitching), and common post-operative myalgia (muscle soreness).
  • Metabolism and Nutrition Disorders: The most significant documented risk is hyperkalemia (elevated serum potassium), which can be severe and life-threatening, particularly when associated with trauma or pre-existing conditions.
  • Immune System Disorders: Include reports of severe, potentially fatal anaphylaxis and other hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the risks of cardiac arrest, malignant hyperthermia, severe hyperkalemia, and prolonged apnea (respiratory depression). The regulatory documents detail specific population-based safety considerations:

  • Pediatric Patients: Are at a higher risk of profound bradycardia and cardiac arrest, particularly following a second dose.
  • Risk Conditions: Use is restricted or contraindicated in patients with major burns, extensive trauma, or underlying conditions like skeletal muscle myopathies due to the high risk of severe hyperkalemia.

Furthermore, the label notes that effects may change with repeated or prolonged exposure, potentially resulting in a prolonged block. The drug must only be administered to a patient who is under full anesthesia as it does not affect consciousness.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Suxamethonium Chloride (Quelicin) is formally defined by an extension of its pharmacological effect, resulting in a prolonged neuromuscular block which manifests as severe and prolonged respiratory depression, ultimately leading to apnea. Regulatory guidance mandates that the medication be administered only when facilities for artificial respiration are instantly available to manage this documented risk.

The official labeling highlights that overexposure or use in susceptible individuals can precipitate life-threatening physiological complications. These include the development of severe hyperkalemia leading to ventricular dysrhythmias and cardiac arrest, as well as the acute onset of Malignant Hyperthermia. Specific populations, such as pediatric patients with undiagnosed muscle myopathy or patients with major burns, are cited as having an increased risk for these severe outcomes.

In such documented situations, immediate medical attention is required. Management involves full supportive measures, including controlled ventilation and the use of specialized agents like intravenous dantrolene sodium for Malignant Hyperthermia. Continuous monitoring of neuromuscular function using a peripheral nerve stimulator is an officially required measure to prevent overdosage during continuous administration.

Therapeutic Uses of Quelicin

Primary Uses of Quelicin

Quelicin is an injectable medication containing succinylcholine chloride, a neuromuscular blocking agent. It is primarily used in clinical settings to induce muscle relaxation. Its main applications include:

  • General Anesthesia: It is frequently administered at the start of surgical procedures to relax the skeletal muscles, which facilitates the surgical process.
  • Endotracheal Intubation: By relaxing the muscles of the jaw, neck, and throat, the medication allows healthcare providers to insert a breathing tube into the trachea more easily and safely.
  • Mechanical Ventilation: In specific medical scenarios, it is used to reduce muscle resistance in patients who require assisted breathing.

How It Works

Quelicin works by mimicking the action of acetylcholine, a natural substance that transmits signals between nerves and muscles. It binds to the receptors on the muscle cells, causing an initial brief contraction followed by a period of paralysis.

Because the medication has a rapid onset and a very short duration of action, it is particularly suited for short procedures or the initial phase of longer operations where immediate muscle relaxation is necessary.

Clinical Benefits

The use of Quelicin provides several benefits in a controlled medical environment:

  • Rapid Response: The medication typically begins working within one minute of administration, allowing for quick transitions in emergency or surgical settings.
  • Brief Duration: Its effects wear off quickly once the administration stops, providing clinicians with precise control over the duration of muscle relaxation.
  • Improved Procedural Safety: By facilitating intubation and preventing involuntary muscle movements during surgery, it helps maintain a stable environment for both the patient and the medical team.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Quelicin (Suxamethonium Chloride) eligibility is strictly defined by government regulatory documents, allowing its use primarily in adult patients.

Eligibility Scope and Contraindications

Use in pediatric patients is severely restricted under a regulatory Boxed Warning, reserving administration exclusively for emergency situations where immediate securing of the airway is necessary.

The medicine is contraindicated and must not be used in patients with a history of malignant hyperthermia or the presence of underlying skeletal muscle myopathies. Absolute prohibition also applies to individuals with inherited atypical plasma cholinesterase activity and congenital myotonic diseases. Quelicin is prohibited in patients who are past the acute injury phase of major burns, multiple trauma, or extensive denervation due to the high risk of life-threatening hyperkalemia.

Conditional and Restricted Use

Use requires caution in patients with severe hepatic disease or renal impairment as reduced metabolic capacity may prolong the drug's effect. For pregnancy, use is not recommended for rapid sequence induction during Cesarean section. Caution is advised during lactation because excretion into human milk is not known.

What should I know about interactions with other medicines?

The official interaction profile for Quelicin (Suxamethonium Chloride) addresses several categories of drug–drug and substance interactions that affect its duration of action and clearance. All interaction information is derived strictly from government regulatory documentation.

Pharmacodynamic and Clearance Interactions

The neuromuscular blocking action of Quelicin is officially documented to be potentiated by co-administration with several medicinal product classes. This includes certain halogenated general anesthetics, aminoglycoside antibiotics (e.g., gentamicin), and antiarrhythmic agents (e.g., quinidine). This potentiation may lead to prolonged paralysis. Separately, substances that reduce the activity of plasma cholinesterase (the enzyme that metabolizes Quelicin), such as certain organophosphorous compounds and oral contraceptives, can decrease the clearance of the drug and result in prolonged systemic exposure and extended neuromuscular blockade.

Critical Restrictions and Incompatibility

A specific restriction is noted regarding cardiac glycosides (e.g., Digoxin). Due to the drug's potential to induce hyperkalemia, its use is restricted in cases of massive digitalis toxicity because of the risk of serious cardiac arrhythmias. Furthermore, Quelicin is acidic and must not be mixed in the same syringe or administered simultaneously with highly alkaline solutions, such as thiopental sodium, due to chemical incompatibility that causes a loss of drug activity. Population-specific considerations also note that individuals with a genetically-determined atypical plasma cholinesterase activity face a high risk of prolonged effect due to impaired metabolism.

Mechanism of Action

Quelicin (succinylcholine) is a depolarizing neuromuscular blocker that exerts its action through two primary mechanistic domains, resulting in the suppression of neuromuscular transmission and subsequent skeletal muscle flaccidity.


Cholinergic Receptor Agonism and Depolarization

Quelicin acts within domains involving receptor-mediated signaling at the motor endplate of skeletal muscles. It functions as an agonist for the nicotinic acetylcholine receptor (nAChR), mimicking the endogenous neurotransmitter acetylcholine. The drug's sustained binding and activation of these receptors initiate a persistent depolarization of the postsynaptic membrane, known as a Phase I block, which involves an initial, transient activation of the motor endplate.


Prolonged Neuromuscular Signal Inhibition

This sustained depolarization modifies key pathways associated with normal muscle excitation, as the voltage-gated sodium channels are held in an inactive state. The inability of these channels to reset prevents the generation of new action potentials, which are necessary for muscle stimulation. This cascade ultimately leads to the suppression of neuromuscular transmission and results in the physiological consequence of rapid onset of skeletal muscle flaccidity.

Dosage and Administration Information

Quelicin (Succinylcholine Chloride Injection) is a sterile solution administered via Intravenous (IV) or Intramuscular (IM) injection only. It is designed for acute use during medical procedures and is not a regularly scheduled medication. Administration must be performed by or under the direct supervision of experienced clinicians who are skilled in artificial respiration management, as facilities for tracheal intubation and ventilation must be instantly available.

Official Administration Guidelines

Administration Aspect Administration Guidelines
Route of Administration Intravenous or Intramuscular use only.
Procedural Condition Must not be administered before unconsciousness has been induced to avoid patient distress. The dosage should be individualized by the clinician after careful assessment.
Adult IV Dosage For short procedures, the average IV dose is 0.6 mg/kg, with an optimum range of 0.3 mg/kg to 1.1 mg/kg. For prolonged procedures, continuous IV infusion may be used, typically at an average rate between 2.5 mg and 4.3 mg per minute.
Pediatric IV Dosage The IV dose is 2 mg/kg for infants and small children, and 1 mg/kg for older children and adolescents, primarily reserved for emergency intubation or immediate airway securing.
Preparation Single-dose vials must be diluted before use. The solution must be visually inspected for particulate matter and discoloration; do not administer if it is not clear and colorless.

When using continuous infusion, neuromuscular function must be monitored with a peripheral nerve stimulator to ensure the required degree of relaxation is maintained. The use of anticholinergics (e.g., atropine) may be considered as a pretreatment to reduce the occurrence of bradyarrhythmias.

Recent Clinical Evidence

Quelicin (succinylcholine chloride) is a depolarizing neuromuscular blocking agent that has been in clinical use for many decades. Due to its unique and rapid-onset pharmacological profile, recent clinical research continues to focus on optimizing its use in critical care and emergency settings, particularly when immediate airway management is required.

Clinical Utility and Speed of Onset

  • Tracheal Intubation: Studies confirm that Quelicin's rapid onset of effect—typically within 60 seconds of intravenous administration—makes it a standard agent for Rapid Sequence Intubation (RSI). Comparative studies primarily evaluate its performance against non-depolarizing agents like rocuronium, focusing on the quality of intubation conditions and the duration of muscle relaxation.
  • Duration of Effect: The short duration of action, usually four to six minutes following a single dose, remains a key feature studied. Research highlights the benefit of this short duration in emergency situations where securing the airway is difficult or when rapid spontaneous breathing recovery is preferred.

Safety and Monitoring Research

Recent research emphasizes refined monitoring and risk management, particularly in specific patient populations:

  • Hyperkalemia and Pediatric Risk: Clinical reports continue to reinforce the association between Quelicin and the risk of hyperkalemia (elevated blood potassium levels), which can lead to serious cardiac events. Due to the potential for fatal dysrhythmias in pediatric patients with undiagnosed muscle conditions, the use of Quelicin in children is generally reserved for emergency intubation or circumstances where alternatives are unavailable.
  • Malignant Hyperthermia: Quelicin is a known trigger for malignant hyperthermia, a rare but severe hypermetabolic state. Ongoing guidance and research emphasize the critical importance of recognizing clinical signs and immediately administering the reversal agent, dantrolene sodium, if this condition is suspected.

Future Directions

Research efforts are directed at objectively measuring the time of onset using tools like Train-of-Four (TOF) stimulation to evaluate the reliability of clinical judgment, ensuring optimal timing for tracheal intubation and enhancing patient safety.

Key Studies & References

  1. A comparison of rocuronium and succinylcholine for facilitating tracheal intubation: a Cochrane review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Quelicin (FAQ)

Q: How long do the effects of Quelicin usually last?

Quelicin is known for its very rapid, short-acting effects. Official information indicates that following a single intravenous dose, the muscle relaxation typically begins quickly—within a minute—and usually lasts for approximately 4 to 6 minutes.

Q: What are the serious side effects of Quelicin that I should be aware of?

Official labeling states that serious risks associated with this drug include rare but severe events such as cardiac arrest, malignant hyperthermia, life-threatening elevation of potassium levels (hyperkalemia), and prolonged apnea (severe difficulty or stoppage of breathing).

Q: What happens if someone has a genetic condition that makes them sensitive to Quelicin?

Individuals who have an inherited lack of the enzyme that breaks down Quelicin (atypical plasma cholinesterase activity) face restrictions on use. Official warnings state that this impaired metabolism can lead to a significantly prolonged effect of the medication, resulting in an extended period of muscle paralysis.

Q: Why is Quelicin rarely used for long surgical procedures?

This medication is characterized as an ultra-short-acting agent. According to clinical and regulatory information, its effects wear off quickly, typically within a few minutes. Because of this brief duration, it is primarily used for quick, critical interventions, rather than for long-term muscle relaxation during lengthy surgeries.

Q: Can certain antibiotics increase the effects of Quelicin?

Yes, official drug interaction profiles indicate that certain medications can potentiate or enhance the effect of Quelicin. Specifically, certain classes of drugs, including aminoglycoside antibiotics, are documented to increase its neuromuscular blocking action, which may prolong the period of muscle relaxation.

Q: Can having low plasma cholinesterase levels affect how Quelicin works?

Yes. If a patient has conditions that reduce the activity of plasma cholinesterase (the enzyme that breaks down Quelicin), the drug’s clearance is decreased. This results in a prolonged presence in the system and an extended duration of the neuromuscular block.

Q: What are the early signs that Quelicin is starting to wear off?

In clinical settings, the level of muscle relaxation is carefully monitored. Monitoring tools like a peripheral nerve stimulator are frequently used by the clinical team to accurately gauge neuromuscular function and confirm the recovery of muscle strength.

Q: Is it normal to feel muscle aches the day after a procedure involving Quelicin?

The possibility of post-operative myalgia (muscle soreness or aching) is listed as an officially documented adverse reaction under Musculoskeletal Disorders. This is a known potential effect of the medication.

Q: Does Quelicin affect breathing on its own, or just the muscles?

Quelicin acts by relaxing all voluntary skeletal muscles, including the diaphragm and other muscles essential for breathing. Because the drug can cause severe respiratory depression or prolonged apnea (stoppage of breathing), the physician must be prepared to manage and control the patient’s breathing immediately upon administration.

Q: Can Quelicin be used in awake patients?

Official administration guidelines note that the medication should generally not be given before the patient has been fully induced with unconsciousness to prevent distress. However, the label does note that in certain emergency situations, the critical need to secure the airway may necessitate an exception.

Q: What's the difference between Quelicin and other muscle relaxants used in surgery?

Quelicin is categorized as a depolarizing neuromuscular blocker, which sets it apart from other non-depolarizing relaxants used in surgery. This difference in mechanism gives Quelicin a unique profile, characterized by a notably fast onset of action and a very short duration of effect.

Q: Can Quelicin cause jaw muscle stiffness or spasms?

Yes. The official adverse reactions list includes documented reports of jaw rigidity (stiffness) under Musculoskeletal disorders. Muscle twitching (fasciculations) is also a common documented effect of the medicine.

Q: Do anesthesiologists have to be careful using Quelicin with heart medications?

The official label notes that caution is required regarding the use of Quelicin alongside certain heart medications. Use is restricted in cases of massive digitalis toxicity (a type of heart medication) due to the drug’s potential to cause hyperkalemia (high potassium) and subsequent serious cardiac rhythm problems.

Q: Is Quelicin safe for children or infants?

Official labeling carries a Boxed Warning that the use of Quelicin in pediatric patients is severely restricted. It is reserved only for emergency circumstances where immediate securing of the airway is critically necessary, as children are at a higher risk for serious cardiac events.

Q: Does Quelicin affect consciousness or memory?

No. Official information confirms that Quelicin is a muscle relaxant and has no direct effect on consciousness, pain threshold, or mental function. It must be administered only after the patient is fully anesthetized or otherwise unconscious.

Q: Is it possible for Quelicin to cause eye pressure changes?

Yes. The drug is associated with a risk of an increase in intraocular pressure (IOP) and this effect is documented under the Eye Disorders category in official product information.

Q: Does the dose of Quelicin change based on the patient's weight?

Yes. The official dosage guidelines for both adults and pediatric patients are given on a milligram per kilogram (mg/kg) basis. This confirms that the dose is determined and individualized by the clinician based on the patient’s body weight.

Q: Why is proper airway management so important when Quelicin is administered?

The drug is a potent skeletal muscle relaxant that affects all voluntary muscles, including those necessary for breathing. For this reason, official warnings mandate that facilities for tracheal intubation and mechanical ventilation must be instantly available, and the clinician must be prepared to fully control the patient’s breathing immediately.

Q: Is there a maximum number of times someone can safely receive Quelicin?

No specific maximum number of administrations is defined in the official label. However, warnings note that the effects of the drug may change with repeated or prolonged exposure, potentially resulting in a longer duration of paralysis.

Q: Does Quelicin have any impact on blood pressure?

Yes, official adverse reaction reports indicate that Quelicin may impact blood pressure. Both hypotension (abnormally low blood pressure) and hypertension (abnormally high blood pressure) are listed as potential documented effects under Cardiovascular Disorders.

Q: Does the drug have a warning for patients with glaucoma?

While the drug is not explicitly contraindicated for all patients with glaucoma, official product information notes an increase in intraocular pressure (IOP) as a possible adverse reaction. This risk is a primary concern for patients with pre-existing eye pressure conditions.

Q: Does having a history of burns affect how Quelicin works?

Yes, the use of Quelicin is prohibited in patients who are past the acute phase of major burns or trauma. This restriction is due to a high risk of causing severe and potentially life-threatening hyperkalemia (elevated blood potassium levels) in these specific patient groups.

How should Quelicin be stored and disposed of?

How to Store and Dispose of Quelicin

Quelicin (succinylcholine chloride injection) must be stored under specific, controlled conditions to preserve its potency as a specialized medication.

Storage Requirements

The injection must be stored in a refrigerator at a temperature between 2 C to 8 C (36 F to 46 F) and must not be frozen. The product requires protection from light and should be stored in its original container. Multi-dose vials are stable for up to 14 days at room temperature (e.g., 25 C or 77 F).

Handling and Disposal

Quelicin must be kept out of the sight and reach of children. Due to the serious risk of accidental administration, the vial must be stored with the cap intact to prevent selection errors. Unused or expired product and related materials must be disposed of according to applicable federal, state, and local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quelicin found in:

A-Z Index: